Education
About Us
Working with TipRanks
Follow Us
Ventyx Biosciences (VTYX)
NASDAQ:VTYX
VTYX Stock Chart & Stats
$3.65
-$0.21(-8.13%)
At close: 4:00 PM EST
$3.65
-$0.21(-8.13%)
Day’s Range― - ―
52-Week Range$0.78 - $4.05
Previous CloseN/A
Volume4.54M
Average Volume (3M)1.18M
Market Cap
$253.86M
Enterprise Value-$46.30M
Total Cash (Recent Filing)$208.96M
Total Debt (Recent Filing)$10.29M
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Nov 12, 2025EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding71,308,520
10 Day Avg. Volume2,045,766
30 Day Avg. Volume1,179,305
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.18
Enterprise Value/Revenue-31.97
Enterprise Value/Gross Profit-503.25
Enterprise Value/Ebitda0.40
Forecast
1Y Price Target
$13.75Price Target Upside276.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical TrialsVentyx recently reported topline data from its open-label Phase 2a study with its CNS-penetrant NLRP3 inhibitor, VTX3232, in early Parkinson’s disease, where target engagement, reductions in downstream biomarkers of NLRP3 inhibition, and safety were demonstrated.
Innovation And R&DVentyx is planning to next conduct a placebo-controlled Phase 2 Parkinson's disease study with VTX3232, and is evaluating additional neurodegenerative disorders such as Alzheimer's disease.
Treatment OutcomesVTX3232 combined with semaglutide led to additive reductions in body weight and food intake, showing potential for improved treatment outcomes.
Bears Say
Competitive ChallengesThe company is not focusing on monotherapy for obesity as the market is highly competitive, indicating challenges in this strategy.
Market CompetitionThe company noted it is mostly interested in results of the semaglutide combo arm which is using a suboptimal dose of semaglutide, and does not believe it makes strategic sense to compete in this space with a monotherapy given obesity is a highly competitive development path.
Strategy ViabilityA significant increase over semaglutide alone is needed to justify the combination approach, presenting a challenge for the company's strategy.
Ventyx Biosciences News
VTYX FAQ
What was Ventyx Biosciences’s price range in the past 12 months?
Ventyx Biosciences lowest stock price was $0.78 and its highest was $4.05 in the past 12 months.
What is Ventyx Biosciences’s market cap?
Ventyx Biosciences’s market cap is $253.86M.
When is Ventyx Biosciences’s upcoming earnings report date?
Ventyx Biosciences’s upcoming earnings report date is Nov 12, 2025 which is in 28 days.
How were Ventyx Biosciences’s earnings last quarter?
Ventyx Biosciences released its earnings results on Aug 07, 2025. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.47 by $0.09.
Is Ventyx Biosciences overvalued?
According to Wall Street analysts Ventyx Biosciences’s price is currently Undervalued.
Does Ventyx Biosciences pay dividends?
Ventyx Biosciences does not currently pay dividends.
What is Ventyx Biosciences’s EPS estimate?
Ventyx Biosciences’s EPS estimate is -0.45.
How many shares outstanding does Ventyx Biosciences have?
Ventyx Biosciences has 71,308,520 shares outstanding.
What happened to Ventyx Biosciences’s price movement after its last earnings report?
Ventyx Biosciences reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.47. Following the earnings report the stock price went up 19.068%.
Which hedge fund is a major shareholder of Ventyx Biosciences?
Currently, no hedge funds are holding shares in VTYX
Ventyx Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.75 (276.71% Upside)
$13.75 (276.71% Upside)
Blogger Sentiment
Bearish
VTYX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 661.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.36%
12-Months-Change
Fundamentals
Return on Equity
-48.56%
Trailing 12-Months
Asset Growth
-25.61%
Trailing 12-Months
Company Description
Ventyx Biosciences
Ventyx Biosciences (VTYX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel, small molecule drugs for the treatment of inflammatory and autoimmune diseases. The company is engaged in the research and development of therapies targeting clinically validated mechanisms, with an emphasis on addressing significant unmet medical needs. Ventyx's core product candidates are designed to modulate key pathways involved in immune system regulation, providing potential new treatments for conditions such as psoriasis, Crohn's disease, and ulcerative colitis.
VTYX Stock 12 Month Forecast
Average Price Target
$13.75
▲(276.71% Upside)
Technical Analysis
Immutep
―
Voyager Therapeutics
―
Silence Therapeutics
―
Foghorn Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
9.73% Insiders
8.79% Mutual Funds
26.36% Other Institutional Investors
50.23% Public Companies and
Individual Investors